Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 18/20 | 0.62 |
| ▸ | TGFBR2 | P37173 | 5/20 | 0.62 |
| ▸ | MAP3K20 | Q9NYL2 | 4/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.60 |
| ▸ | THRB | P10828 | 6/20 | 0.59 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24311946 | 0.92 | TGFBR1 (0.60) | TGFBR1TGFBR2MAP3K20CYP2D6THRB | |
| SCHEMBL4822129 | 0.91 | TGFBR1 (0.59) | TGFBR1TGFBR2MAP3K20CYP2D6THRB | |
| SCHEMBL4821254 | 0.91 | TGFBR1 (0.63) | TGFBR1TGFBR2MAP3K20CYP2D6THRB | |
| SCHEMBL24312011 | 0.91 | TGFBR1 (0.61) | TGFBR1TGFBR2MAP3K20CYP2D6THRB | |
| SCHEMBL14108283 | 0.90 | TGFBR1 (0.66) | TGFBR1TGFBR2MAP3K20CYP2D6THRB | |
| SCHEMBL4815976 | 0.84 | TGFBR1 (0.67) | TGFBR1TGFBR2MAP3K20CYP2D6THRB | |
| SCHEMBL4821382 | 0.84 | TGFBR1 (0.56) | TGFBR1TGFBR2MAP3K20CYP2D6THRB | |
| SCHEMBL24312353 | 0.83 | TGFBR1 (0.64) | TGFBR1TGFBR2MAP3K20CYP2D6THRB | |
| SCHEMBL4821493 | 0.82 | TGFBR1 (0.63) | TGFBR1TGFBR2MAP3K20CYP2D6THRB | |
| SCHEMBL4822897 | 0.82 | TGFBR1 (0.73) | TGFBR1TGFBR2MAP3K20CYP2D6THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7405299-B2 | Compounds as pharmaceutical agents | ELI LILLY AND COMPANY (US) | 2008-07-29 | — | — | US | claimed |
| EP-1567527-A1 | CONDENSED PYRAZOLO DERIVATIVES | ELI LILLY AND COMPANY (US) | 2005-08-31 | — | — | EP | claimed |
| WO-2004050659-A1 | NOVEL COMPOUNDS AS PHARMACEUTICAL AGENTS | ELI LILLY AND COMPANY (US) | 2004-06-17 | — | — | WO | claimed |
| US-8815920-B2 | Substituted amide compound | ASTELLAS PHARMA INC. (JP) | 2014-08-26 | — | — | US | disclosed |
| US-7405299-B2 | Compounds as pharmaceutical agents | ELI LILLY AND COMPANY (US) | 2008-07-29 | — | — | US | disclosed |
| US-7405299-B2 | Compounds as pharmaceutical agents | ELI LILLY AND COMPANY (US) | 2008-07-29 | — | — | US | disclosed |
| US-7405299-B2 | Compounds as pharmaceutical agents | ELI LILLY AND COMPANY (US) | 2008-07-29 | — | — | US | disclosed |
| US-7368445-B2 | Fused pyrazole derivatives as TGF-β signal transduction inhibitors for the treatment of fibrosis and neoplasms | ELI LILLY AND COMPANY (US) | 2008-05-06 | — | — | US | disclosed |
| US-7368445-B2 | Fused pyrazole derivatives as TGF-β signal transduction inhibitors for the treatment of fibrosis and neoplasms | ELI LILLY AND COMPANY (US) | 2008-05-06 | — | — | US | disclosed |
| US-7368445-B2 | Fused pyrazole derivatives as TGF-β signal transduction inhibitors for the treatment of fibrosis and neoplasms | ELI LILLY AND COMPANY (US) | 2008-05-06 | — | — | US | disclosed |
| US-20070155722-A1 | Fused pyrazole derivatives as tgf-beta signal transduction inhibitors for the treatment of fibrosis and neoplasms | ELI LILLY AND COMPANY (US) | 2007-07-05 | — | — | US | disclosed |
| US-20070155722-A1 | Fused pyrazole derivatives as tgf-beta signal transduction inhibitors for the treatment of fibrosis and neoplasms | ELI LILLY AND COMPANY (US) | 2007-07-05 | — | — | US | disclosed |
| US-20070155722-A1 | Fused pyrazole derivatives as tgf-beta signal transduction inhibitors for the treatment of fibrosis and neoplasms | ELI LILLY AND COMPANY (US) | 2007-07-05 | — | — | US | disclosed |
| EP-1723146-A1 | FUSED PYRAZOLE DERIVATIVES AS TGF-BETA SIGNAL TRANSDUCTION INHIBITORS FOR THE TREATMENT OF FIBROSIS AND NEOPLASMS | ELI LILLY AND COMPANY (US) | 2006-11-22 | — | — | EP | disclosed |
| US-20060058295-A1 | Novel compounds as pharmaceutical agents | ELI LILLY AND COMPANY (US) | 2006-03-16 | — | — | US | disclosed |
| WO-2005092894-A1 | FUSED PYRAZOLE DERIVATIVES AS TGF-BETA SIGNAL TRANSDUCTION INHIBITORS FOR THE TREATMENT OF FIBROSIS AND NEOPLASMS | ELI LILLY AND COMPANY (US) | 2005-10-06 | — | — | WO | disclosed |
| EP-1567527-A1 | CONDENSED PYRAZOLO DERIVATIVES | ELI LILLY AND COMPANY (US) | 2005-08-31 | — | — | EP | disclosed |
| WO-2004050659-A1 | NOVEL COMPOUNDS AS PHARMACEUTICAL AGENTS | ELI LILLY AND COMPANY (US) | 2004-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058295-A1 | Novel compounds as pharmaceutical agents | TGFB1, TGFB2, TGFBR1 | TGFBR1 3/4885TGFBR2 4/4885MAP3K20 105/4885 |
| US-20070155722-A1 | Fused pyrazole derivatives as tgf-beta signal transduction inhibitors for the treatment of fibrosis and neoplasms | SMAD3, TGFBR1, TGFBR2 | TGFBR1 2/4885TGFBR2 3/4885MAP3K20 77/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.